Search | Clinical Trials Finder

Conditions: Retinopathy of Prematurity (ROP)
Interventions: rhIGF-I/rhIGFBP-3; Drug
Lead sponsor: Shire; Industry
Eligibility: Up to 1 Day
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Mobile, Alabama • Irvine, California • Augusta, Georgia + 5 more

Conditions: Alteration of Cognitive Function
Interventions: Exercise Challenge; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Pasireotide, Everolimus; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions: Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss; Drug · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acromegaly
Interventions: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions: BYL719, AMG 479; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Skin Cancer
Interventions: Fractional Laser and Chemical Peel; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer, Overweight and Obesity
Interventions: Aerobic Exercise; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 79 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography; Genetic · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 180
States / cities: Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more

Conditions: Hypopituitarism
Interventions: Human Growth Hormone (1-134), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: IGF1 Deficiency
Interventions: Increlex®; Drug
Lead sponsor: Esteve Pharmaceuticals, S.A.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 7
States / cities: Orange, California • Miami, Florida • Cincinnati, Ohio + 2 more

Conditions: Bone; Disorder, Development and Growth
Interventions: Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions: rhIGF-1 (mecasermin, Tercica, Inc.); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 34
States / cities: Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more

Conditions: Acromegaly, Type 2 Diabetes Mellitus
Interventions: Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo; Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more

Conditions: Acromegaly
Interventions: Somatuline Autogel (lanreotide acetate), Home administration; Drug · Behavioral
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: La Mesa, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions: [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose; Drug · Biological
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions: Increlex; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 20 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thyroid Eye Disease (TED)
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more

Conditions: Noonan Syndrome
Interventions: rhIGF-1/rhIGFBP-3; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
U.S. locations: 2
States / cities: New Hyde Park, New York • Columbus, Ohio

Conditions: Healthy
Interventions: Mexican or American foods; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Interventions: Dasatinib, Ganitumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Search by objective public record fields.

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Exercise and Cognition Trials

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Survivorship Promotion In Reducing IGF-1 Trial

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

COMIDAS Comparing Original Mexican Diets and Standard US Diets

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma